EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Profile of certolizumab and its potential in the treatment of psoriatic arthritis



Profile of certolizumab and its potential in the treatment of psoriatic arthritis



Drug Design, Development and Therapy 7: 339-348



Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with psoriasis (PsO). PsA could be considered an enthesal disease because of the link between mechanical stress (entheses) and immunologically active tissue (synovium). Evidence of efficacy of anti-tumor necrosis factor alpha (TNF-α) is supported by reduction of histological vascularity and immune cell infiltrates in synovial tissue after treatment. Certolizumab pegol (CZP) is a polyethylene glycolylated (PEGylated) Fab' fragment of a humanized monoclonal antibody that binds and neutralizes human TNF-α. The PEG moiety of the Fab fragment, markedly increases the half-life of CZP and confers to the drug a unique structure that differs from the other anti-TNF-α agents tested for the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis, nonradiographic spondyloarthritis, PsO, and PsA. In contrast to other anti-TNF-α agents, CZP did not mediate increased levels of apoptosis, suggesting that these mechanisms are not essential for the anti-TNF-α efficacy in Crohn's disease. As CZP, infliximab, and adalimumab, but not etanercept, almost completely inhibited lipopolysaccharide-induced interleukin-1 beta release from monocytes, this cytokine-production inhibition may be relevant for drug efficacy. Due to these characteristics, it has been demonstrated in clinical studies that CZP effectively improves signs and symptoms of arthritis and physical function and skin manifestations of PsO, with a safety profile similar to rheumatoid arthritis. This drug can be considered as a valid treatment in patients affected by PsA. The efficacy and tolerability profiles suggest CZP as a suitable antipsoriatic drug in the treatment of PsA.

(PDF same-day service: $19.90)

Accession: 055205380

Download citation: RISBibTeXText

PMID: 23620660

DOI: 10.2147/DDDT.S31658



Related references

Cost-Effectiveness of Certolizumab Pegol in the Treatment of Active Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis In Romania. Value in Health 17(7): A379-A379, 2014

Certolizumab pegol for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology 11(3): 307-318, 2015

Determination of size-segregated elements in diesel-biodiesel blend exhaust emissions. Environmental Science and Pollution Research International, 2018

Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis. Open Access Rheumatology 6(): 7-13, 2014

New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol. Journal of Rheumatology. Supplement 93: 70-72, 2016

Budget Impact Analysis of Certolizumab Pegol for The Treatment of Active Psoriatic Arthritis In Greece. Value in Health 18(7): A638-A639, 2015

Cost-Utility Analysis of Certolizumab Pegol for the Treatment of Active Psoriatic Arthritis in GREECE. Value in Health 18(7): A646-A647, 2015

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. Open Access Rheumatology 8(): 37-44, 2016

Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis. Medical Letter on Drugs and Therapeutics 56(1435): 10-12, 2014

Validation of an original questionnaire for patients with psoriatic arthritis: the Psoriatic Arthritis Impact Profile (PAIP). La Clinica Terapeutica 165(2): E100-E108, 2015

Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis. Drugs 74(9): 999-1016, 2015

Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Annals of the Rheumatic Diseases 74(1): 44-51, 2015

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. Rmd Open 1(1): E000119-E000119, 2015

Sustained Improvements in Workplace and Household Productivity and Social Participation With Certolizumab Pegol Over 96 Weeks in Patients With Psoriatic Arthritis. Value in Health 17(7): A387-A388, 2014

A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F)). Clinical Rheumatology 34(8): 1407-1412, 2016